Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gensight Biologics SA

0.2400
+0.0000
Volume:- -
Turnover:- -
Market Cap:27.64M
PE:-1.59
High:0.2400
Open:0.2400
Low:0.2400
Close:0.2400
Loading ...

Company Profile

Company Name:
Gensight Biologics SA
Exchange:
EXPERT
Establishment Date:
2012
Employees:
16
Office Location:
74, rue du Faubourg Saint-Antoine,Paris,Ile-de-France,France
Website:
- -
Zip Code:
75012
Fax:
- -
Introduction:
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.